Enodia Therapeutics
Develops small-molecule therapies for targeted protein degradation at the point of synthesis
€20.7MSeed
Role not disclosedWE
Wallonie Entreprendre
Activity from announced rounds
Activity in this selectionFrance
Wallonie Entreprendre is the public investor identified through its Enodia announcement and Chift and Novadip coverage.
Recorded funding activity
Enodia develops protein-degradation medicines. Chift connects financial software APIs, while Novadip develops regenerative cell therapies. W.IN.G and named regional funds remain distinct from the public investor.
- Rounds participated in
- 1
- Confirmed lead rounds
- — 1 roles undisclosed
- New companies
- 1 First participation on record · 0 follow-on
- Funding in participating rounds
- $24.2M 1 disclosed · full round size, not this investor’s share